The invention relates to a new pharmacotherapeutical strategy, to an anti-stress, anti-impairment and anti-aging drug and to a process for itsmanufacturing. The drug has an etio-pathogenic and homeostatic action, waspreclinically tested and clinically checked up in geriatric, neurologic,psychiatric and stress-dependent pathology. The drug achieves a synergisticbiological, neurometabolic and cell-trophic composition, being elaborated bythe association of the following active principles: a) against oxidative andcatabolic stress: methionine with aminoethanol phenoxyacetates and/oraminoethyl phenoxyacetamides; b) against anabolic stress: hydrooxopyrimidinecarboxylates and/or oxopyrrolidine acetamides with potassium, zinc andlithium; c) vasodilative and normolipidemic: nicotinic, alcohol and/or acid,or its derivatives, with magnesium and iodine; d) energo-active and e) anti-toxic: aspartate; fructose; vitamin B1; vitamin B6; monoacid phosphate andsulfate. The process for manufacturing the drug stipulates: a) pharmaceuticalpreparation in two complementary types of capsules or coated tablets,gastrosoluble and enterosoluble, the last being enteric coated; b) prolonged-release of vasodilator from the enterosoluble unit.
展开▼
